AGM
PRQR icon

Alpine Global Management’s ProQR Therapeutics PRQR Stock Holding History

Alpine Global Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,749
Closed -$39.1K – 195
2024
Q4 		$39.1K Buy
+14,749
New +$46.8K 0.01% 154

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Alpine Global Management's PRQR Position: Q1 2025 in Review

Alpine Global Management sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 14,749 shares — an estimated $39.1K sold.

Alpine Global Management first reported a position in PRQR in Q4 2024 and held it in 1 quarter. The position peaked at $39.1K in Q4 2024. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

  • Alpine Global Management reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Alpine Global Management sold 14,749 ProQR Therapeutics shares in Q1 2025, an estimated $39.1K.
  • Alpine Global Management first reported a position in ProQR Therapeutics in Q4 2024 and held it in 1 quarter.
  • Alpine Global Management's ProQR Therapeutics position peaked at $39.1K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.